Estimates of Chronic Kidney Diseases Associated with Proton-Pump Inhibitors Using a Retrospective Hospital-Based Cohort in Thailand

References

• Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep. 2019;9(1). doi:10.1038/s41598-019-39335-7
   Web of Science ®Google Scholar
• Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–297. doi:10.1177/2042098617715381
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–1494. doi:10.1016/j.kint.2016.12.021
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–139. doi:10.1038/nrd1010
   PubMed Web of Science ®Google Scholar
• World Health Organization. 21st WHO Model List of Essential Medicines. World Health Organization; 2019.
   Google Scholar
• Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS One. 2013;8(2):e56060. doi:10.1371/journal.pone.0056060
   PubMed Web of Science ®Google Scholar
• Chariyawet P, Dilokthornsakul P. Omeprazole overuse and its financial loss in a community hospital. J Pharm Pract. 2018;10(2):12.
   Google Scholar
• Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018;3(6):457–462. doi:10.1002/lio2.187
   PubMed Web of Science ®Google Scholar
• Aguilera AI, Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero G. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One. 2018;13(10):e0204231. doi:10.1371/journal.pone.0204231
   PubMed Web of Science ®Google Scholar
• Guedes JVM, Aquino JA, Castro TLB, et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344.
   PubMed Web of Science ®Google Scholar
• Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–246. doi:10.1001/jamainternmed.2015.7193
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–3163. doi:10.1681/ASN.2015121377
   PubMed Web of Science ®Google Scholar
• Hung SC, Liao KF, Hung HC, et al. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. Fam Pract. 2018;35(2):166–171. doi:10.1093/fampra/cmx102
   PubMed Web of Science ®Google Scholar
• Cholin L, Ashour T, Mehdi A, et al. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol. 2021;22(1):264. doi:10.1186/s12882-021-02449-0
   PubMed Web of Science ®Google Scholar
• Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–342. doi:10.1093/ndt/gfw470
   PubMed Web of Science ®Google Scholar
• Parker MM, Moffet HH, Adams A, Karter AJ. An algorithm to identify medication nonpersistence using electronic pharmacy databases. JAMIA. 2015;22(5):957–961. doi:10.1093/jamia/ocv054
   Web of Science ®Google Scholar
• Sakaguchi Y, Tsubakihara Y, Rakugi H, Isaka Y. Does hypomagnesemia predict faster progression of nondiabetic chronic kidney disease? Am J Med. 2014;127(2):e13. doi:10.1016/j.amjmed.2013.08.020
   PubMed Web of Science ®Google Scholar
• Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med. 2013;126(9):825–831. doi:10.1016/j.amjmed.2013.02.036
   PubMed Web of Science ®Google Scholar
• Yang D, Dalton JE A unified approach to measuring the effect size between two groups using SAS; 2012.
   Google Scholar
• Zhao QY, Luo JC, Su Y, Zhang YJ, Tu GW, Luo Z. Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021;9(9):812. doi:10.21037/atm-20-3998
   PubMed Web of Science ®Google Scholar
• Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the medication possession ratio. Patient Prefer Adherence. 2017;11:1469–1478. doi:10.2147/PPA.S136890
   PubMed Web of Science ®Google Scholar
• Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PLoS One. 2017;12(4):e0174426. doi:10.1371/journal.pone.0174426
   PubMed Web of Science ®Google Scholar
• Rajan P, Iglay K, Rhodes T, Girman CJ, Bennett D, Kalantar-Zadeh K. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. Therap Adv Gastroenterol. 2022;15:17562848221074183. doi:10.1177/17562848221074183
   Web of Science ®Google Scholar
• Yang F, Wittes J, Pitt B. Beware of on-treatment safety analyses. Clin Trials. 2019;16(1):63–70. doi:10.1177/1740774518812774
   PubMed Web of Science ®Google Scholar
• Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221–228. doi:10.1007/s40471-015-0053-5
   PubMedGoogle Scholar
• Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437–441. doi:10.1038/nrrheum.2015.30
   PubMed Web of Science ®Google Scholar